{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:38:37Z","timestamp":1786804717891,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ordos Health Commission Key discipline Project"},{"name":"Inner Mongolia Medical University Science and Technology million Project funding"},{"name":"Ordos science and technology project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>A prospective randomized controlled trial was conducted to compare 5\u00a0mg olanzapine plus standard triple antiemetic therapy for the prevention of nausea and vomiting induced by multiple-day cisplatin chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\n<\/jats:title>\n                <jats:p>Patients who received a 3-day cisplatin-based chemotherapy (25\u00a0mg\/m<jats:sup>2<\/jats:sup>\/d) were given either 5\u00a0mg olanzapine plus triple therapy with aprepitant, tropisetron, and dexamethasone (quadruple group) or 5\u00a0mg olanzapine plus tropisetron and dexamethasone, omitting aprepitant (triplet group). The primary endpoint was the complete response (CR) in the overall phase (OP) (0\u2013120\u00a0h) between quadruple group and triplet group. The secondary endpoints were the CR in the acute phase (AP) (0\u201324\u00a0h) and delayed phase (DP) (25\u2013120\u00a0h) between two groups. The first time of vomiting was also compared by Kaplan\u2013Meier curves. The impact of chemotherapy-induced nausea and vomiting (CINV) on the quality of life was assessed by the Functional Living Index-Emesis (FLIE). Aprepitant-related adverse effects (AEs) were also recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>(1) The primary endpoint CR during OP was 76.0% (45\/59) vs 67.0% (41\/61) between the quadruple group and triplet group (<jats:italic>P<\/jats:italic>\u2009=\u20090.271). The secondary endpoint CR during the AP was significantly higher in the quadruple group than in the triplet group, which was 100.0% (59\/59) vs 93.0% (57\/61) (<jats:italic>P<\/jats:italic>\u2009=\u20090.045). The difference of CR during delayed phase between the groups was especially higher in the quadruple group compared to the triplet group (76.0% (45\/59) vs 67.0% (41\/61) (<jats:italic>P<\/jats:italic>\u2009=\u20090.271)). The rate of patients who achieved total protection in the overall phase was also higher in the quadruple group than the triplet group (28.8% (17\/59) vs 23.0% (14\/61) (<jats:italic>P<\/jats:italic>\u2009=\u20090.463)). During the OP, the incidence of no vomiting in the quadruple group and the triplet group was 93.2% (55\/59) vs 80.3% (49\/61) (<jats:italic>P<\/jats:italic>\u2009=\u20090.038), respectively. (2) Kaplan\u2013Meier curves of time to first emesis were obviously longer in the quadruple group compared with the triplet group (<jats:italic>P<\/jats:italic>\u2009=\u20090.031). According to FLIE, no impact of CINV on daily life was defined as total score of questionnaire\u2009&gt;\u2009108; this study exhibited identical life quality between two groups. (3) The most common aprepitant- or olanzapine-related AEs included sedation, fatigue, and constipation. The occurrences between two groups were identical.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion\n<\/jats:title>\n                <jats:p>It may been recommended that 5\u00a0mg olanzapine plus tropisetron and dexamethasone, omitting aprepitant triplet regimen as an alternative therapy in prevention CINV induced by multiple-day cisplatin chemotherapy due to the excellent CINV control rate and safety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07067-6","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T19:40:38Z","timestamp":1650570038000},"page":"6225-6232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Olanzapine (5\u00a0mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study"],"prefix":"10.1007","volume":"30","author":[{"given":"Jiali","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanzhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungaowa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenggaowa","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowa","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"issue":"1","key":"7067_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25(1):277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"key":"7067_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","volume":"34","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Bohlke K, Lyman GH (2016) Antiementics: Americian Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381\u2013386","journal-title":"J Clin Oncol"},{"key":"7067_CR3","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C et al (2012) Randomized, double-blind, placebo controlled phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5 day-cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"7067_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1515\/med-2018-0005","volume":"13","author":"Q Li","year":"2018","unstructured":"Li Q, Wang W, Chen G et al (2018) Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting. Open Med (Wars) 13:29\u201334","journal-title":"Open Med (Wars)"},{"key":"7067_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting:time for more emphasis on nausea? Oncologist 20:576\u2013583","journal-title":"Oncologist"},{"key":"7067_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"issue":"2","key":"7067_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"Y Takako","year":"2018","unstructured":"Takako Y, Satoru I, Hironobu H, Fumiyoshi O, Tomomi T, Koji T, Masahiko N, Hiroshi S, Toshiaki N, Koichi M, Takahiro A, Kenichi S, Yasuhiro S, Kengo N, Hiroyuki T, Noboru Y (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388. https:\/\/doi.org\/10.1007\/s10147-017-1200-4","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"7067_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hironobu","year":"2020","unstructured":"Hironobu H, Masakazu A, Osamu T, Hideaki M, Yosuke U, Takuhiro Y, Yukari H, Yasuhiko S, Yanai TT, Kazuhisa N, Masahiko N, Daisuke T, Sadamoto Z, Koki M, Satoru I, Michiru S, Noboru Y, Yuichiro O (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"issue":"10","key":"7067_CR9","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/bcp.13322","volume":"83","author":"P Priya","year":"2017","unstructured":"Priya P, Steven LJ, Micheline P-M, Lee DL (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 83(10):2148\u20132162. https:\/\/doi.org\/10.1111\/bcp.13322","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"7067_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone[J]. Clin Pharmacol Ther 74(1):17\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(03)00066-3","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"7067_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer 11(8):522\u2013527","journal-title":"Support Care Cancer"},{"issue":"1","key":"7067_CR12","first-page":"35","volume":"4","author":"GM Decker","year":"2006","unstructured":"Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J]. J Support Oncol 4(1):35-41 52","journal-title":"J Support Oncol"},{"issue":"10","key":"7067_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0959-8049(03)00299-5","volume":"39","author":"AR Martin","year":"2003","unstructured":"Martin AR, Carides AD, Pearson JD et al (2003) Functional relevance of antiemetic control:experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant[J]. Eur J Cancer 39(10):1395\u20131401","journal-title":"Eur J Cancer"},{"issue":"2","key":"7067_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting[J]. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"issue":"3","key":"7067_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study[J]. J Pain Symptom Manage 47(3):542\u2013550","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"7067_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, Mcfarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J]. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"1","key":"7067_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1445-5994.2011.02637.x","volume":"43","author":"HF Gao","year":"2013","unstructured":"Gao HF, Liang Y, Zhou NN et al (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy[J]. Intern Med J 43(1):73\u201376","journal-title":"Intern Med J"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07067-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07067-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07067-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:33:43Z","timestamp":1653557623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07067-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["7067"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07067-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Ordos Central Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this article and any accompanying images. A copy of the written consent is available for review by the editor in chief of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}